TickerGuard
Buy Day today: Neutral (47) Mixed market breadth · no major macro event
KURA

Kura Oncology Inc

Healthcare · Biotechnology

10.70$ +1.3% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet KURA
Line item 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
100.0% 85.6% 91.5% 100.0% 100.0% 72.4% 86.8% 99.6% 98.6% 98.7% 99.4% 99.0% 98.5% 97.8% 97.8% 96.3% 98.0% 96.0%
100.0% 85.6% 91.5% 62.8% 57.8% 72.4% 81.6% 17.7% 13.9% 11.9% 8.8% 10.8% 50.3% 17.0% 11.4% 8.3% 29.5% 20.2%
100.0% 85.6% 91.5% 62.8% 57.8% 72.4% 81.6% 98.3% 97.1% 97.2% 98.1% 97.9% 97.9% 97.0% 96.0% 94.4% 95.7% 90.4%
– – – – – – 2.2% 0.5% 0.4% 0.2% 0.1% 0.0% – 0.3% 0.2% 0.6% 0.8% 1.7%
– – – – – – – – – – – – – – – – 0.0% 0.1%
– – – – – – 2.0% 0.1% 0.1% 0.0% – 0.1% 0.3% 0.5% 0.6% – – –
– 242.9% 239.4% 1,112.4% 1,248.5% 1,467.0% 349.1% 5.9% 18.5% 16.7% 11.7% 9.6% 5.6% 5.1% 7.9% 11.5% 45.6% 76.4%
– 192.1% 204.1% 1,112.4% 1,248.5% 1,216.9% 218.9% 5.8% 7.8% 10.5% 7.5% 6.4% 4.0% 4.2% 5.3% 7.9% 10.4% 15.8%
– 192.1% 204.1% 892.9% 1,023.8% 1,213.1% 147.8% – 10.5% 1.6% – 0.2% 0.8% 0.4% 0.5% 0.3% 0.6% 0.2%
– – – 43.6% 22.3% 3.9% 16.4% 1.1% 2.0% 1.3% 2.2% 1.5% 0.4% 0.6% 0.3% 0.5% 0.2% 0.7%
– – – – – – 35.8% 8.4% 10.5% 5.8% 4.1% 3.0% 0.7% – 2.0% 2.1% 0.9% 1.3%
18.6% -142.9% -139.4% -1,012.4% -1,148.5% -1,367.0% -249.1% 94.1% 81.5% 83.3% 88.3% 90.4% 94.4% 94.9% 92.1% 88.5% 54.4% 23.6%
-647.3% -527.0% -309.5% -1,756.4% -1,750.7% -1,918.4% -266.4% -30.1% -77.1% -93.2% -82.1% -88.0% -46.7% -81.1% -124.7% -160.7% -117.8% -159.0%
66,595.6% 38,411.3% 17,008.0% 74,404.8% 60,226.5% 55,139.0% 297.0% 11.4% 26.8% 24.2% 19.3% 17.3% 8.2% 12.4% 14.7% 16.3% 11.3% 11.9%

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?